We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Lawmakers Call on GAO to Investigate Power Morcellators

Lawmakers Call on GAO to Investigate Power Morcellators

September 25, 2015

A bipartisan group of lawmakers is calling on the head of the U.S. Government Accountability Office to investigate why power morcellators remained on the market for more than two decades before being slapped with a black box warning last year.

“Hundreds, if not thousands, of women in America are dead,” because of the power morcellator, which is used to remove uterine fibroids, the lawmakers say. They cite historical studies going as far back as 1990 showing the increased risk of spreading cancer in women.

“Despite these studies, as late as last year, the FDA, the medical device industry, and many gynecologists pointed to the risk of a hidden cancer as being low, only 1-in-10,000,” the letter states. “How did they get it so wrong for so long?”

Morcellators came under scrutiny after the FDA issued a safety alert last year saying the instrument’s blades could spread unsuspected cancers in as many as one in 352 cases.

As part of the probe into morcellator safety, the group is asking GAO to consider the following:

  • Did the FDA’s reliance on 510(k) clearance sufficiently identify risks before morcellators came to market?
  • Were medical device reporting regulations followed appropriately by manufacturers, importers, user facilities and the FDA?
  • What activities or training did manufacturers provide clinicians, and what professional society standards were applied for training on the use of these devices?
  • What additional steps are being taken, beyond the black box warning, to determine whether the devices are safe to remain on the market?

The Aug. 7 letter was signed by Reps. Mike Fitzpatrick (R-Pa.), Louise Slaughter (D-N.Y.), Ralph Abraham (R-La.), Rosa DeLauro (D-Conn.), Bill Pascrell, Jr., (D-N.J.), Lou Barletta, (R-Pa.), Doug LaMalfa, (R-Calif.), Anna Eshoo (D-Calif.), Jan Schakowsky (D-Ill.), Chris Smith (R-N.J.), Stephen Lynch (D-Mass.) and Rick Larsen (D-Wash.).

During markup of the 21st Century Cares Act, which passed the House last month, Fitzpatrick offered seven amendments focused on getting unsafe devices off the market, particularly power morcellators. None of the amendments made the final bill.

Stay up to date on regulatory stories like this one by subscribing to The GMP Letter. For 30 years, devicemakers have relied on GMP for the latest on the FDA's interpretation and enforcement of cGMPs and the Quality Systems Regulation.

Medical Devices Quality QSR

Upcoming Events

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

  • 07Mar

    FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

  • 08Mar

    Medical Device Cybersecurity: The Regulatory Landscape and How to Defend Your Practices During an Inspection

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Boston Scientific’s Single Use Ureteroscope Gets FDA Clearance

  • Gilead’s Trodelvy Gets Expanded Approval in Breast Cancer

  • AI Software to Improve Echocardiogram Images Gets FDA Clearance

  • Rocket Pharmaceuticals Gets RMAT Designation for Danon Disease Gene Therapy

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing